文献速递乳腺癌

低危乳腺癌保乳术后内分泌治疗联合或不联合全乳放疗:ABCSG 8A 试验10年结果

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
PubMed 文献 · Eur J Cancer · 2020-01-18

奥地利乳腺癌与结直肠癌研究组8A试验将869例激素受体阳性乳腺癌保乳术后患者随机分为全乳放疗组(439例)和观察组(430例),均接受内分泌治疗。中位随访9.89年,全乳放疗组10年局部无复发生存率97.5%显著高于观察组92.4%(p=0.004),无病生存率亦显著提高(94.5% vs 88.4%,p=0.0156),远处转移无生存率和总生存率无显著差异。

要点

  • 保乳术后内分泌治疗联合全乳放疗较单纯内分泌治疗显著改善10年局部控制(97.5% vs 92.4%)。
  • 联合放疗组10年无病生存率显著更高(94.5% vs 88.4%,p=0.0156)。
  • 远处转移无生存率和总生存率两组无显著差异。

核心结论

  • 中位随访约10年,保乳术后内分泌治疗联合全乳放疗较单纯内分泌治疗显著改善局部控制和无病生存。

研究设计与样本

  • 奥地利乳腺癌与结直肠癌研究组8A试验,869例激素受体阳性乳腺癌保乳术后患者随机接受全乳放疗(439例)或观察(430例),均接受内分泌治疗。
  • 全乳放疗平均总剂量50 Gy(±10 Gy推量),常规分割。

主要发现

  • 中位随访9.89年,放疗组发生10例乳腺内复发,观察组31例。
  • 10年局部无复发生存率放疗组97.5%,观察组92.4%(p=0.004)。
  • 10年无病生存率放疗组94.5%,观察组88.4%(p=0.0156)。
  • 10年远处转移无生存率放疗组96.7%,观察组96.4%;总生存率放疗组86.6%,观察组87.6%(均无显著差异)。
  • 多因素Cox回归显示全乳放疗(HR 0.27,p<0.01)和肿瘤分级(HR 3.76,p=0.03)是乳腺内复发的显著预测因素。

关键数值与推荐

  • 全乳放疗组10年局部无复发生存率97.5%,观察组92.4%(p=0.004)。
  • 全乳放疗组10年无病生存率94.5%,观察组88.4%(p=0.0156)。
  • 全乳放疗对乳腺内复发的HR为0.27(p<0.01),肿瘤分级HR为3.76(p=0.03)。

临床怎么用

  • 对于低危激素受体阳性乳腺癌保乳术后患者,联合全乳放疗可显著改善局部控制和无病生存,支持全乳放疗作为该人群的标准辅助治疗组成部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate long-term results of patients with hormonal receptor-positive breast cancer treated with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). METHODS AND MATERIALS: Within the 8 A trial of the Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS which was randomly followed by WBI (n = 439, group 1) or observation (n = 430, group 2). WBI was applied up to a mean total dosage of 50 Gy (+/- 10 Gy boost) in conventional fractionation. RESULTS: After a median follow-up of 9.89 years, 10 in-breast recurrences (IBRs) were observed in group 1 and 31 in group 2, resulting in a 10-year local recurrence-free survival (LRFS) of 97.5% and 92.4%, respectively (p = 0.004). This translated into significantly higher rates for disease-free survival (DFS): 94.5% group 1 vs 88.4% group 2, p = 0.0156. For distant metastases-free survival (DMFS) and overall survival (OS), respective 10-year rates amounted 96.7% and 86.6% for group 1 versus 96.4% and 87.6%, for group 2 (ns). WBI (hazard ratio [HR]: 0.27, p < 0.01) and tumour grading (HR: 3.76, p = 0.03) were found as significant predictors for IBR in multiple cox regression analysis. CONCLUSIONS: After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone. The omission of WBI and tumour grading, respectively, were the only negative predictors for LRFS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fastner G, Sedlmayer F, Widder J, et al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. Eur J Cancer. 2020. PMID: 31962198. doi:10.1016/j.ejca.2019.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。